An open-label, multicenter, Phase I trial evaluating the pharmacokinetics, safety, and efficacy of mosunetuzumab as a single agent in patients with relapsed or refractory follicular lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 20 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Mar 2024 Results (Study GO29781 n=90 and YO43555 , n=17) assessing Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics (Pk) in Chinese Patients with Relapsed or Refractory Follicular Lymphoma presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
14 Sep 2023 Planned End Date changed from 31 Dec 2023 to 21 Apr 2025.
02 Jun 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com